Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer

Matthew G. Field; H. Culver Boldt; Taher Abu Hejleh; Elaine M. Binkley

doi:10.1016/j.ajoc.2022.101459

Back

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer

Journal article

Open access

Peer reviewed

Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer

Matthew G. Field, H. Culver Boldt, Taher Abu Hejleh and Elaine M. Binkley

American journal of ophthalmology case reports, Vol.26, 101459

06/01/2022

DOI: 10.1016/j.ajoc.2022.101459

PMCID: PMC8899229

PMID: 35265776

Files and links (1)

url

https://doi.org/10.1016/j.ajoc.2022.101459View

Published (Version of record) Open Access

Abstract

Purpose: Describe the use of osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as the first-line treatment in a patient with choroidal and central nervous system metastases from EGFR-mutated non-small cell lung cancer. Observations: A 68-year-old man presented with an amelanotic choroidal lesion in the left eye concerning for choroidal metastasis. Systemic evaluation identified widely metastatic adenocarcinoma of the lung with EGFR exon 19 mutation. Within one month of initiating treatment with osimertinib, there was complete resolution of the subretinal fluid over the choroidal lesion and decreased thickness of the lesion. At follow-up after three months of treatment, the lesion was clinically involuted. Positron emission tomography at two months and magnetic resonance imaging of the brain at three months showed significant interval decrease in size and activity of the primary right lung lesion, central nervous system lesions, and other metastatic sites with no new metastatic lesions. After 17 months of follow up, the lesion remained involuted. Conclusions and Importance: Osimertinib may be considered as a first-line treatment option in patients with choroidal metastases from an EGFR-mutated non-small cell lung cancer.

Choroidal metastasis

EGFR

Epidermal growth factor receptor

Lung adenocarcinoma

Osimertinib

Tyrosine kinase inhibitor

Details

Title: Subtitle: Successful response to first-line treatment with osimertinib for choroidal metastasis from EGFR-mutated non-small-cell lung cancer
Creators: Matthew G. Field - University of Iowa
H. Culver Boldt - University of Iowa
Taher Abu Hejleh - University of Iowa
Elaine M. Binkley - University of Iowa
Resource Type: Journal article
Publication Details: American journal of ophthalmology case reports, Vol.26, 101459
DOI: 10.1016/j.ajoc.2022.101459
PMID: 35265776
PMCID: PMC8899229
NLM abbreviation: Am J Ophthalmol Case Rep
ISSN: 2451-9936
eISSN: 2451-9936
Publisher: Elsevier
Language: English
Date published: 06/01/2022
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine; Ophthalmology and Visual Sciences
Record Identifier: 9984225460302771

Metrics

8 Record Views